BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target
BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
A smart money expert says Orchestra BioMed is now worth buying and thinks the stock could go to $10. When experts change their mind to say something is better, it means they found good reasons to believe in the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.